Benefit of aerosol therapy with pulmozyme for children with cystic fibrosis

S. Dumcius, A. Valiulis, L. Indrejaityte (Vilnius, Lithuania)

Source: Annual Congress 2005 - Cystic fibrosis: of exercise, aerosol and more
Session: Cystic fibrosis: of exercise, aerosol and more
Session type: Thematic Poster Session
Number: 3954
Disease area: Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Dumcius, A. Valiulis, L. Indrejaityte (Vilnius, Lithuania). Benefit of aerosol therapy with pulmozyme for children with cystic fibrosis. Eur Respir J 2005; 26: Suppl. 49, 3954

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Inhalation therapy in cystic fibrosis
Source: School Course 2013 - Cystic Fibrosis
Year: 2013

Inhaled mannitol as treatment for children with cystic fibrosis
Source: Annual Congress 2008 - The use of inhaled mannitol for assessing airway disease
Year: 2008


Compliance with treatment in UK children with cystic fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 538s
Year: 2001

Efficacy of alendronate/colecalciferol/calcium in adults with cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more
Year: 2010


Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014


Long-term tiotropium bromide therapy was retrospectively analyzed in adults with cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015

Long-term administration of aerosolised tobramycin in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 619s
Year: 2005

Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis
Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways
Year: 2013

Home intravenous antibiotic treatments in cystic fibrosis adult patients
Source: Eur Respir J 2002; 20: Suppl. 38, 158s
Year: 2002

Ergospirometry in children with cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 229s
Year: 2003

Optimising inhaled mannitol for cystic fibrosis in an adult population
Source: Breathe 2015; 11:39-48
Year: 2015



Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016


Lung deposition of inhaled colistimethate sodium in cystic fibrosis patients
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

Prescription of Inhaled corticosteroid in non-cystic fibrosis bronchiectasis:a solution or a problem
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020


NIV for children with cystic fibrosis
Source: ERS Course 2017 - Paediatric noninvasive ventilation
Year: 2017

Safety of endobronchial biopsy in children with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 727s
Year: 2005

Control of the inhalation technique in cystic fibrosis patients
Source: Eur Respir J 2006; 28: Suppl. 50, 262s
Year: 2006